Peptide InjectionsAI
High evidence

Orforglipron

Peptide therapy: benefits, side effects, cost and protocols

C48H48F2N10O5

883 g/mol / CID 137319706
C48H48F2N10O5

Orforglipron is an experimental oral non-peptide GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable semaglutide and tirzepatide, it is a small molecule taken daily by mouth, potentially offering a more convenient weight loss and diabetes treatment option.

ByChris Riley(CFA)|Updated

Sources: FDA / PubMed / ClinicalTrials.gov View

FDA status
FDA-approved drug
Evidence
Strong Evidence

Who Orforglipron is usually considered for

  • Oral administration (no injection)
  • Weight loss potential
  • Blood sugar regulation
  • Convenient daily pill

How Orforglipron works

Small-molecule oral GLP-1 receptor agonist that activates the same pathways as injectable GLP-1 drugs without requiring injection.

Key studies

168 papers on PubMed

  1. 01

    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment

  2. 02

    Wharton S, Aronne LJ, Stefanski A et al

    N Engl J Med / Phase 3

    Orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks.

  3. 03

    Orforglipron 36 mg reduced body weight by 11.2% versus 2.1% with placebo over 72 weeks

  4. 04

    Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

  5. 05

    Horn DB, Ryan DH, Kis SG et al

    Lancet / Phase 3

    Orforglipron 36 mg reduced body weight by 9.6% vs 2.5% placebo in adults with obesity and type 2 diabetes.

  6. 06

    Orforglipron 36 mg reduced body weight by 9.6% vs 2.5% placebo in adults with obesity and type 2 diabetes

  7. 07

    Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes

  8. 08

    Rosenstock J, Hsia S, Nevarez Ruiz L et al

    N Engl J Med / Phase 3

    Orforglipron reduced HbA1c by 1.24-1.48 percentage points and body weight by 4.5-7.6% versus placebo.

  9. 09

    Orforglipron reduced HbA1c by 1.24-1.48 percentage points and body weight by 4.5-7.6% versus placebo

  10. 10

    Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study

Orforglipron compound data

C48H48F2N10O5
883.0 g/mol
137319706 ↗
3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyltetrahydropyran-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethyl-phenyl)-3-[3-(4-fluoro-1-methyl-indazol-5-yl)-2-oxo-imidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methyl-cyclopropyl]-4H-1,2,4-oxadiazol-5-one

Orforglipron questions

What is ORFORGLIPRON?

Orforglipron is an investigational oral non-peptide GLP-1 receptor agonist being developed by Eli Lilly. Currently in Phase 3 clinical trials, it could become the first oral non-peptide GLP-1 agonist if approved.

How does ORFORGLIPRON work?

Small-molecule oral GLP-1 receptor agonist that activates the same pathways as injectable GLP-1 drugs without requiring injection.

Is ORFORGLIPRON legal to buy?

ORFORGLIPRON is sold as a research chemical for laboratory use only. It is not approved for human use by the FDA. Regulations vary by jurisdiction.

Where can I buy ORFORGLIPRON?

ORFORGLIPRON is available as a research compound from verified online vendors. Always verify third-party testing before purchasing.

What category does ORFORGLIPRON belong to?

ORFORGLIPRON is primarily classified as a weight loss & metabolic peptide. Peptides researched for their effects on weight management, fat metabolism, appetite regulation, and metabolic enhancement. This category includes GLP-1 agonists, dual/triple agonists, and other metabolic peptides.

What are the research benefits of ORFORGLIPRON?

ORFORGLIPRON has been studied for: Oral administration (no injection), Weight loss potential, Blood sugar regulation, Convenient daily pill. Phase 3 trials by Eli Lilly. First oral non-peptide GLP-1 agonist if approved.

Orforglipron in the news

News aggregated via Google News. Inclusion does not imply endorsement.

Considering Orforglipron?

The 2-minute quiz matches you with licensed providers who offer it. A clinician decides if it fits.

Take the quiz